Payment overview · 2025
General Payments
$83.05
6 reported records · 4 companies
Healthcare provider profile · identity verified
Caroline Steinman, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · VINCENNES, IN · NPI 1750643573
Verified facts
What the public records show
CMS Open Payments records show Caroline Steinman, D.O. received $83.05 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 61.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.13 | 61.6% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.48 | 18.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.96 | 16.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $2.48 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.05 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.13 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $2.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 609 | 110 |
| Omeprazole | Omeprazole | 533 | 105 |
| Lisinopril | Lisinopril | 501 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 93 |
| Montelukast Sodium | Montelukast Sodium | 395 | 72 |
| Gabapentin | Gabapentin | 360 | 64 |
| Furosemide | Furosemide | 340 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 296 | 65 |
| Potassium Chloride | Potassium Chloride | 288 | 67 |
| Losartan Potassium | Losartan Potassium | 267 | 57 |
| Meloxicam | Meloxicam | 253 | 52 |
| Bupropion Xl | Bupropion Hcl | 234 | 49 |
| Metformin Hcl | Metformin Hcl | 214 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 38 |
| Trazodone Hcl | Trazodone Hcl | 208 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 38 |
| Metformin Hcl Er | Metformin Hcl | 193 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 41 |
| Ozempic | Semaglutide | 175 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 29 |
| Pregabalin | Pregabalin | 167 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 37 |
| Buspirone Hcl | Buspirone Hcl | 158 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 25 |
| Simvastatin | Simvastatin | 136 | 29 |
| Mounjaro | Tirzepatide | 132 | 19 |
| Famotidine | Famotidine | 128 | 21 |
| Tramadol Hcl | Tramadol Hcl | 128 | 25 |
| Azelastine Hcl | Azelastine Hcl | 126 | 52 |
| Baclofen | Baclofen | 119 | 28 |
| Eliquis | Apixaban | 115 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 113 | 13 |
| Alprazolam | Alprazolam | 109 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 18 |
| Warfarin Sodium | Warfarin Sodium | 95 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 17 |
| Nystatin | Nystatin | 91 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 26 |
| Prednisone | Prednisone | 85 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 78 | 11 |
| Bumetanide | Bumetanide | 77 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 14 |
| Allopurinol | Allopurinol | 72 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | 11 |
| Trulicity | Dulaglutide | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 16 |
| Glimepiride | Glimepiride | 64 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 12 |
| Farxiga | Dapagliflozin Propanediol | 61 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Carvedilol | Carvedilol | 56 | 21 |
| Clonazepam | Clonazepam | 56 | 13 |
| Atenolol | Atenolol | 55 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 11 |
| Promethazine Hcl | Promethazine Hcl | 55 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Topiramate | Topiramate | 54 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | suppressed |
| Spironolactone | Spironolactone | 52 | 15 |
| Glipizide | Glipizide | 51 | 13 |
| Klor-Con M20 | Potassium Chloride | 51 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 19 |
| Sertraline Hcl | Sertraline Hcl | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 13 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | 11 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Metolazone | Metolazone | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Cimetidine | Cimetidine | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 22 |
| Cephalexin | Cephalexin | 26 | 19 |
| Diazepam | Diazepam | 26 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 21 | suppressed |
| Qulipta | Atogepant | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Belsomra | Suvorexant | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Junel | Norethindrone Ac/Eth Estradiol | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Portia | Levonorgestrel/Ethin.Estradiol | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Testosterone | Testosterone | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.05 · 6 records | ABBVIE INC. | ABRYSVO, COMIRNATY, IBSRELA, NEXPLANON, PREVNAR 20, QULIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error